Table 1.

Interactions between Nirmatrelvir tablets/Ritonavir tablets (Paxlovid^®) and anticancer drugs^[56]

Anticancer drug	Nirmatrelvir tablet/Ritonavir tablets	Explanation
Almonertinib	Combination prohibited	A) The combination of 2 drugs affects the efficacy of Paxlovid®; B) The combination of the 2 drugs leads to high drug concentration causing severe adverse events; C) Discontinue, consider resuming the administration 3 days after the use of Paxlovid®.
Vometinib	Combination prohibited
Gefitinib	Obvious interaction, preferably switch or discontinue	Discontinue or change to other alternative drugs. If necessary, pay close attention to the patient's symptoms and discontinue the drug in a timely manner.
Erlotinib	Obvious interaction, preferably switch or discontinue
Afatinib	Obvious interaction, preferably switch or discontinue
Savolitinib	Weak interaction, may be combined	Only partially metabolized by CYP3A4, weak interaction, low risk of severe adverse events. No action required.
Osimertinib	Can be used in combination	No interaction
Alectinib	Can be used in combination
Pemetrexed	Can be used in combination
Dacotinib	Can be used in combination